Streptococcus Pyogenes Infections Pipeline Review, H1 2019 Edition - ResearchAndMarkets.com

DUBLIN--()--The "Streptococcus pyogenes Infections - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Streptococcus pyogenes Infections - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcus pyogenes Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in IND/CTA Filed, Preclinical and Discovery stages are 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Streptococcus pyogenes Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Streptococcus pyogenes Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Streptococcus pyogenes Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease)

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Streptococcus pyogenes Infections - Overview
  4. Streptococcus pyogenes Infections - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Streptococcus pyogenes Infections - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development
  • Absynth Biologics Ltd
  • AstraZeneca Plc
  • Cadila Pharmaceuticals Ltd
  • Crestone Inc
  • Helix BioMedix Inc
  • Wellstat Vaccines LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r7ufxb

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900